Bavarian Nordic Secures $63 Million U.S. Government Contract for Vaccine Production

Bavarian Nordic has secured a $63 million contract from the U.S. government to produce the Jynneos vaccine for mpox and smallpox. The Danish company will manufacture 1 million freeze-dried doses by 2026. This deal aims to replenish vaccine stock depleted during the 2022 mpox outbreak, now considered a global public health emergency.

Bavarian Nordic has clinched a $63 million contract from the U.S. government aimed at boosting the production of its Jynneos vaccine for mpox and smallpox, the company announced on Tuesday.

According to the contract terms, the Danish biotech firm will produce 1 million freeze-dried vaccines by 2026. The bulk of the contract's value will go toward replenishing inventory used during the 2022 mpox outbreak.

The World Health Organization recently declared mpox a global public health emergency following an outbreak in the Democratic Republic of Congo. The viral infection, which has spread to neighboring regions, is typically mild but can be fatal in rare cases, causing flu-like symptoms and pus-filled lesions.

(With inputs from agencies.)